Key finding
Finerenone significantly reduced the risk of the key secondary kidney outcome (hazard ratio 0.48; 95% confidence interval 0.29–0.79; p = 0.0029).
The FIGARO-DKD trial subgroup analysis evaluated finerenone in patients with type 2 diabetes and chronic kidney disease, finding significant reductions in kidney failure risk.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Quick read
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Finerenone, Placebo
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Time to cardiovascular death
Comparator
Placebo
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
The FIGARO-DKD trial subgroup analysis evaluated finerenone in patients with type 2 diabetes and chronic kidney disease, finding significant reductions in kidney failure risk.
These findings are significant as they suggest that finerenone can be an effective treatment option for patients with type 2 diabetes and chronic kidney disease, potentially improving kidney health and reducing the need for dialysis or transplantation. This is particularly important given the rising prevalence of diabetes and its complications.
The effectiveness of finerenone on cardiovascular death was not statistically significant. The study may have limited generalizability to broader populations. The sample size and duration may not capture long-term effects.
Published in
Publication details and source links for this paper.
Ping L, Hongguang Z, Jianhua M, et al. Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Subgroup Analysis of the FIGARO-DKD Trial. Frontiers in Endocrinology. 2025;16:1568438. doi:10.3389/fendo.2025.1568438
Save this study and add notes to your research library.
Finerenone significantly reduced the risk of kidney failure (hazard ratio 0.48; p = 0.0029).
Finerenone showed a numerical decrease in the risk of cardiovascular death (hazard ratio 0.91).
The incidence of hyperkalemia was low across treatment arms.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Incidence of hyperkalemia, Time to cardiovascular death, Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death.
This study contributes evidence to
Primary intervention
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
3
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of hyperkalemia
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of hyperkalemia
Evidence profile
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Time to cardiovascular death
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Time to cardiovascular death
Evidence profile
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death
Evidence profile
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Contributes to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) evidence base.
All studies measuring Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death
Measures Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time to kidney failure, sustained eGFR decline ≥40% from baseline, or kidney-related death
EvidenceScore™ Emerging | EvidenceScore™ 50.3 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Finerenone (nonsteroidal mineralocorticoid receptor antagonist) for Incidence of hyperkalemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Incidence of hyperkalemia
EvidenceScore™ Limited | EvidenceScore™ 32.8 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Finerenone (nonsteroidal mineralocorticoid receptor antagonist) for Time to cardiovascular death.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time to cardiovascular death
EvidenceScore™ Limited | EvidenceScore™ 32.8 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
